Vaccinex

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

At Vaccinex, our mission is to improve the lives of patients through generating transformative science-driven therapies. Our efforts are focused on creating treatments that reduce suffering caused by disease and extend the quality of life of patients and their families.

Vaccinex’s vision is to improve the health and well-being of people throughout the world by continuously innovating, developing, commercializing and implementing clinical-stage therapeutic programs.

Vaccinex has been recognized with numerous awards over the years, including the Pro Bono Publico award, the Small Business Innovation Research award, and the Red Hotel Biotech Award.